Elizabeth G. Nabel - 03 May 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 03 May 2024
Net transactions value: $0
Form type: 4
Filing time: 07 May 2024, 16:48:44 UTC
Previous filing: 03 May 2024
Next filing: 03 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise		+732	+53%		2,105	03 May 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-732	-100%	$0.000000^*	0	03 May 2024	Common Stock	732		Direct	F1, F2
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+5,668		$0.000000	5,668	06 May 2024	Common Stock	5,668	$122.13	Direct	F3
transaction	MRNA	Restricted Stock Units	Award	$0	+979		$0.000000	979	06 May 2024	Common Stock	979		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	The shares subject to this restricted stock unit award vested in full on May 3, 2024.
F3	This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F4	The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.